Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Diabetic Medicine

Volumn 30, Issue 11, 2013, Pages 1293-1297

  Bode, B W ^a   Buse, J B ^b   Fisher, M ^c   Garg, S K ^d   Marre, M ^e   Merker, L ^f   Renard, E ^g   Russell Jones, D L ^h   Hansen, C T ⁱ   Rana, A ⁱ   Heller, S R ^j  

^a ATLANTA DIABETES ASSOCIATES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF COLORADO DENVER   (United States)

^e BICHAT HOSPITAL   (France)

^f Diabetes und Nierenzentrum   (Germany)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

ⁱ NOVO NORDISK A S   (Denmark)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE;

ARTICLE; BOLUS INJECTION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; GALLBLADDER CANCER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SUDDEN DEATH;

ANALYSIS OF VARIANCE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, LONG-ACTING; INSULINS; MALE; TREATMENT OUTCOME;

EID: 84885920592     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12243     Document Type: Article

References (6)

1. Tibaldi JM. Evolution of insulin development: focus on key parameters. Adv Ther 2012; 29: 590-619.
2. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
3. Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175-184.
4. ® Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
5. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34: 661-665.
6. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.